Inversely, ET particularly orally administered estrogens are considered as counteract metabolic factors increasing the risk of BC, which were achieved by increasing insulin sensitivity and lowering circulating insulin levels [86], and this study suggested similar results that oral-ET had highest BC risk than transdermal and virginal use. The gene discussed is INS; the disease is breast cancer.